Travis Williams, DO
Medical Oncology · Meridian, IDNPI 1043461817
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,260 of the $49,939 with a category attached, or 74.6%. Gilead accounts for 88.4% of it on its own, with 23 other manufacturers making up the rest.
Across 74 payments — averaging $674.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$44K
- GSK$2K
- Sanofi$2K
- Johnson & Johnson$336
- AstraZeneca$265
- Collegium Pharmaceutical, Inc.$226
- plus $1K from 18 others
Across 9 payments — averaging $758.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$7K
What the payments were for
- Consulting fees$7,26415%
- Speaking & faculty fees$37,26075%
- Travel & lodging$2,4035%
- Food & beverage$2,7345%
- Education$2781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 22 | $44,146 |
| GSK | 3 | $2,093 |
| Sanofi | 3 | $1,819 |
| Johnson & Johnson | 4 | $336 |
| AstraZeneca(2 entities) | 5 | $265 |
| Collegium Pharmaceutical, Inc. | 13 | $226 |
| Seagen Inc. | 2 | $189 |
| Astellas Pharma US Inc | 3 | $128 |
| Exelixis Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $103 |
| Daiichi Sankyo Inc. | 1 | $59 |
| Pacira Therapeutics, Inc. | 2 | $43 |
| Sumitomo Pharma America, Inc. | 1 | $42 |
| AbbVie | 2 | $40 |
| Janssen Scientific Affairs, LLC | 2 | $39 |
| Amgen | 1 | $33 |
| Bristol Myers Squibb | 1 | $26 |
| EMD Serono, Inc. | 1 | $25 |
| Biogen | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Tanabe Pharma America, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 74 | $1,401,519 |
| RevlimidLenalidomide | 36 | $672,590 |
| JakafiRuxolitinib Phosphate | 44 | $668,002 |
| BrukinsaZanubrutinib | 25 | $291,968 |
| TasignaNilotinib Hcl | 15 | $221,184 |
| VenclextaVenetoclax | 29 | $181,127 |
| SprycelDasatinib | 12 | $164,910 |
| CalquenceAcalabrutinib Maleate | 13 | $129,774 |
| ValacyclovirValacyclovir Hcl | 11 | $2,071 |
| Acyclovir | 60 | $1,449 |
| Potassium Chloride | 20 | $484 |
| Dexamethasone | 22 | $423 |
| Levofloxacin | 21 | $303 |
| Ondansetron OdtOndansetron | 20 | $223 |
| Mirtazapine | 12 | $205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $103 | $1,566,43086 claims |
| Bristol Myers SquibbRevlimid | $26 | $672,59036 claims |
| AbbVieVenclexta | $40 | $181,12729 claims |
| AstraZenecaCalquence | $265 | $129,77413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Meridian
- Silvana BucurMeridian$262
- Peyman HaghighatMeridian$112
- Muhammad BegBoise$99K
- Cannon MilaniBoise$9K
- Sushma PantLewiston$8K
- Gerardo MidenceLewiston$1K
- Daniel WilliamsLewiston$1K
- Katrina RolenLewiston$947
- Gwendoline FonebiPocatello$675
- Abeer ArainLewiston$649
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.